Published in Ann Intern Med on September 04, 2012
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One (2013) 5.01
The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis (2013) 3.59
Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis (2014) 2.14
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS (2014) 1.86
Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS (2013) 1.49
End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis (2014) 1.23
Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol (2013) 1.15
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06
Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS (2014) 1.05
Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr (2014) 1.00
HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis (2014) 1.00
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol (2014) 0.93
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011. BMC Infect Dis (2014) 0.92
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.91
The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. PLoS One (2015) 0.91
Strong agreement of nationally recommended retention measures from the Institute of Medicine and Department of Health and Human Services. PLoS One (2014) 0.91
Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol (2015) 0.90
A Matter of Perspective: Comparison of the Characteristics of Persons with HIV Infection in the United States from the HIV Outpatient Study, Medical Monitoring Project, and National HIV Surveillance System. Open AIDS J (2015) 0.89
Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013. Clin Infect Dis (2016) 0.88
Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001-2011. J Acquir Immune Defic Syndr (2015) 0.84
Increased Antiretroviral Therapy Use and Virologic Suppression in the Bronx in the Context of Multiple HIV Prevention Strategies. AIDS Res Hum Retroviruses (2016) 0.84
Progress realized: trends in HIV-1 viral load and CD4 cell count in a tertiary-care center from 1999 through 2011. PLoS One (2013) 0.83
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts. J Int AIDS Soc (2016) 0.82
Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. AIDS (2016) 0.82
Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis (2016) 0.82
Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One (2016) 0.81
Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. AIDS (2015) 0.81
Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study. HIV Clin Trials (2015) 0.81
Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One (2013) 0.78
Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. AIDS Patient Care STDS (2015) 0.78
Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. J Viral Hepat (2015) 0.76
Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. J Clin Oncol (2016) 0.76
Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceive. J Int AIDS Soc (2015) 0.76
Cohort profile: seek, test, treat and retain United States criminal justice cohort. Subst Abuse Treat Prev Policy (2017) 0.75
Comparison of HIV outcomes for patients linked at hospital versus community-based clinics. AIDS Patient Care STDS (2015) 0.75
Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS (2017) 0.75
Health Outcomes of HIV-Infected People with Mental Illness. AIDS Behav (2015) 0.75
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis (2016) 0.75
Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors. Am J Transplant (2017) 0.75
Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. R I Med J (2013) (2014) 0.75
Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention: Results from the HPTN 065 Study. J Int Assoc Provid AIDS Care (2016) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA (1999) 10.93
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med (1998) 6.26
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 5.49
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis (2006) 4.67
HIV surveillance--United States, 1981-2008. MMWR Morb Mortal Wkly Rep (2011) 4.30
Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health (1991) 4.16
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Mixed effects models with censored data with application to HIV RNA levels. Biometrics (1999) 2.74
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed (2004) 2.23
Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr (2012) 2.15
Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One (2007) 2.08
Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol (2010) 2.07
Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med (2009) 1.63
Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses (2007) 1.61
Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses (2010) 1.58
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54
Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr (2009) 1.45
Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007. MMWR Surveill Summ (2011) 1.42
Delayed presentation for human immunodeficiency virus (HIV) care among veterans: a problem of access or screening? Med Care (2007) 1.32
Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS (2006) 1.30
Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care (2007) 1.20
Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther (2011) 1.11
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS (2009) 1.10
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection (2011) 1.03
Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Community Health (2008) 0.94
Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. J Gen Intern Med (2011) 0.94
Trends in uptake of recently approved antiretrovirals within a national healthcare system. HIV Med (2009) 0.82
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Hybrid error correction and de novo assembly of single-molecule sequencing reads. Nat Biotechnol (2012) 10.31
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Tuberculosis. Lancet (2003) 6.39
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 5.49
Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet (2006) 5.34
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr (2010) 4.32
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care (2006) 4.28
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS (2009) 3.78
The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2007) 3.76
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep (2014) 3.60
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38